A decrease of BRCA1 expression in response to CCCP treatment was observed in various breast cancer cell lines tested as well as in lung cancer and a neuroblastoma cell line, all of which express wild-type BRCA1 (Fig. 1a). This evidence concerns the gene BRCA1 and breast carcinoma.